Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial.
Schjesvold FredrikHartmut GoldschmidtVladimir MaisnarIvan SpickaNeils AbildgaardPhilip RowlingsLauren CainDorothy RomanusKaveri SuryanarayanVincent RajkumarDawn OdomAri GnanasakthyMeletios- Athanasios DimopoulosPublished in: European journal of haematology (2020)
In addition to improvement in progression-free survival with ixazomib, HRQoL was maintained in both arms. Active treatment with ixazomib did not have an adverse impact on HRQoL.